From SRUK
Research into Raynaud’s syndrome has often been conducted in relation to systemic sclerosis, however it is critical to remember that it is its own condition that has the potential to be extremely detrimental to a person’s quality of life. It is crucial that research is conducted into areas such as treatment, diagnoses, and causes.
Those experiencing Raynaud’s have traditionally been advised to manage their symptoms by minimising exposure to cold, reducing stress and smoking cessations. These are all suggestions that are far easier said than done, meaning that in most instances, drugs such as calcium channel blockers are administered, with well known medications being nifedipine (Adalat has been discontinued, but other brands such as Nifedipress MR are still available) and iloprost. However, these options are not always effective and successful in limiting the symptoms and decreasing impact on daily life.
To read the full published research CLICK HERE
